Avecia Biotechnology has entered an agreement with Pfizer for the commercial supply of a key component of Pfizer’s Macugen (pegaptanib sodium injection). Pfizer markets the drug in the E.U. for the treatment of wet Age-Related Macular Degeneration. The agreement includes technology transfer, process validation and commercial supply of a key component of Macugen.

“The agreement with Pfizer to manufacture a key component of this commercial oligonucleotide-based therapeutic is testament to our experience, reliability and quality standards with regard to technology transfer, process validation and the manufacture of oligonucleotide drug substances,” says Detlef Rethage, president of Avecia Biotechnology. Avecia was acquired by Merck in December 2009.